CAR-T cell therapy for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with multiple myeloma that has come back or not responded to several prior treatments. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have given consent.
- Your multiple myeloma has come back or did not respond to at least three prior treatments, including specific types of drugs.
- You have measurable signs of myeloma, like certain levels of protein in your blood or urine.
- You are in reasonably good health, able to care for yourself, and have recovered from side effects of past treatments.
- You do not have serious infections, organ problems, or other conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to find and attack a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has come back or not responded to at least three prior treatments.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
Hear when a new Relapsed/Refractory Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.